Online
|
|
bn market drug
Posted by :
tara23ok... ok.. i have not seen the denomination correctly......
bn market drug
Posted by : LEO THE LION
dear tara its $130 mn = 625 + crs
this is really great....
bn market drug
Posted by : tara23it is 130cr.. only......
bn market drug
Posted by : LEO THE LION
I guess wock`s nutritional division divested at around 250-300 cr.
a accurate figure not yet received.
have you observed what khorakiwala said...?
Wock will record robust results...........the words,he used....
bn market drug
Posted by : LEO THE LION
I held cadila bought at 250`s, sold in between for some other reason and acuumulated when it was at 300`s sold at 375 for other reasons.
Now you will see a robust results from wock going forward.acumulate wock at every dip..........
bn market drug
Posted by : tara23no not at all.. i am seriously telling...
bn market drug
Posted by : LEO THE LION
you are just kidding...
:-)...
bn market drug
Posted by : tara23you are rocking.... and ur stocks are rocketing......
bn market drug
Posted by : pratiksmiling
thanks for info. dear LTL
r u join this march?...
bn market drug
Posted by : LEO THE LION
Cadila continuing its march........ahead.
it at 450+ now....
Buy Cadila Healthcare
Posted by :
insight95in
Cadila Healthcare
Buy
Price: Rs 402 Target Price (Mar 10): Rs 505
Climbing on all fronts
Net profit up 39% YoY: Cadila reported 1Q10 39% YoY growth in net profit to Rs1.25bn vs. our estimate of Rs1.04bn. EBITDA margins were in line at 22.6% - flat YoY. Net sales were up 27% YoY to Rs9bn - above our expectation of Rs7.8bn due to higher sales across segments.
All segments grow: Domestic formulations grew 13% YoY aided by launch of 17 new products and was above expectation. US formulations showed significant growth to Rs1.5bn (Rs320m profits – pre-R&D) supported by launch of mycophenolate generic. The management maintained that it would cross its $100m sales guidance from this region in FY10. Other geographies continued to contribute in formulations – France Rs599mn (+30% YoY), Spain 39m, Japan 84mn, S. Africa 168mn and RoW at Rs358mn. Brazil was down by 14% YoY at Rs366mn (c.8% rupee appreciation against Brazilian currency) but should recover going forward. Consumer segment was up 28% YoY while API was steady at 7% YoY growth.
Hospira commences, Nycomed steady: Hospira JV contribution kicked in from this quarter with combined sales at Rs468mn and profit of Rs128mn. Cadila shares 50%. Presently 3 products are launched through this JV for European markets. This will be gradually expanded to additional products. Exports to US will start from end-FY10. Nycomed JV contributed Rs294m sales and Rs205m profits. The
management maintains guidance of Rs620mn sales and Rs350mn profits from Nycomed and Rs800m sales guidance for Hospira JV.
Costs in control: Gross margin has expanded by 200bps mainly due to rupee depreciation with stable staff costs. Other expenditure includes Rs76mn forex loss on translation and additional Rs120m due to recent acquisitions. R&D expense at Rs469mn (vs. Rs390m in 1Q09). Debt is at c.Rs12bn. 1-2 ANDAs filed in the quarter.
Revising estimates, Maintain BUY: We are revising FY10 and FY11 EPS estimates by 2% and 4% respectively. We revise our Mar-10 to Rs505 on 15x FY11E EPS. Our previous target price was based on 12x. We maintain BUY.
...
BSE Announcements on Cadila Health
Posted by : MMB Messenger
Cadila Healthcare Ltd has announced the following Unaudited results for the quarter ended June 30, 2009:
The Company has posted a net profit of Rs 1225.60 million for the quarter ended June 30, 2009 where as the same was at Rs 556.40 million for the quarter ended June 30, 2008. Total Income is Rs 6083.80 million for the quarter ended June 30, 2009 where as the same was at Rs 4947.80 million for the quarter ended June 30, 2008.
The standalone figures of Cadila Healthcare Ltd for the current quarter are not comparable with the figures of corresponding quarter of previous year because of demerger of Consumer Products Division, which got merged with Zydus Wellness Ltd, a subsidiary of Cadila Healthcare Ltd.
The Consolidated Results are as follows
The Group has posted a net profit of Rs 1247.90 million for the quarter ended June 30, 2009 as compared to Rs 896.80 million for the quarter ended June 30, 2008. Total Income has increased from Rs 7156.20 million for the quarter ended June 30, 2008 to Rs 9077.60 million for the quarter ended June 30, 2009....
NSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 46527 lacs for quarter ending on 30-JUN-2009 against Rs. 48213 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12256 lacs for the quarter ending on 30-JUN-2009 against Rs. 5564 lacs for the quarter ending on 30-JUN-2008....
NSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 88031 lacs for quarter ending on 30-JUN-2009 against Rs. 68571 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 12479 lacs for the quarter ending on 30-JUN-2009 against Rs. 8968 lacs for the quarter ending on 30-JUN-2008....
NSE Announcements on Cadila Health
Posted by : MMB MessengerCadila Healthcare Limited has informed the Exchange regarding a press release dated July 27, 2009, titled "Zydus Cadila Q1 Net Profit surges by 39%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). ...
